Cannabis and Cachexia
What the evidence actually says about cannabinoids for the wasting syndrome seen in cancer, HIV/AIDS, and other chronic diseases.
Cannabis has a real, FDA-recognized role in HIV/AIDS wasting — that's where dronabinol (synthetic THC) got approved in 1992. For cancer cachexia, the story is messier: THC reliably increases appetite and the enjoyment of food, but it doesn't consistently translate into the lean body mass gains that actually matter for survival. Megestrol acetate outperformed dronabinol head-to-head. So: useful for appetite and quality of life, not a proven anti-wasting drug. This is not medical advice.
Plain-language summary
Cachexia is involuntary weight loss — specifically loss of muscle mass — that occurs in cancer, HIV/AIDS, heart failure, COPD, and end-stage kidney disease. It's not just 'not eating enough.' It's a metabolic syndrome driven by inflammation and altered protein metabolism, and you can't fully reverse it by adding calories.
THC, the main psychoactive cannabinoid, stimulates appetite. This is well established Strong evidence [1][2]. The harder question is whether stimulating appetite in a cachectic patient translates into meaningful gains in muscle mass, function, and survival. The short answer: in HIV/AIDS, yes, modestly [3]. In cancer cachexia, the evidence is disappointing [4][5].
This article is not medical advice. Cachexia is a serious clinical condition. Decisions about cannabinoids, megestrol, corticosteroids, or any other intervention should be made with your oncology, palliative care, or infectious disease team.
What probably works
Dronabinol for HIV/AIDS-associated anorexia. Synthetic THC (dronabinol, brand names Marinol and Syndros) was approved by the FDA in 1992 specifically for anorexia associated with weight loss in patients with AIDS Strong evidence. The pivotal trial by Beal and colleagues showed significant improvements in appetite and a trend toward weight gain over six weeks compared to placebo [1]. A longer open-label follow-up showed sustained appetite improvement and modest weight stabilization [2].
THC for appetite and food enjoyment, generally. Across populations, THC reliably increases self-reported appetite, hunger ratings, and pleasure from eating Strong evidence. This is mediated through CB1 receptor activity in the hypothalamus and the mesolimbic reward system [6]. A small RCT in advanced cancer patients found that THC (not CBD) improved chemosensory perception and food enjoyment, even when total caloric intake didn't change dramatically [7].
So cannabinoids can make eating feel possible and pleasurable again. That alone has real palliative value, even when it doesn't reverse the underlying wasting.
What might work (weak or mixed evidence)
Cannabinoids for cancer-related appetite loss. A 2006 Cannabis-In-Cachexia-Study-Group RCT compared THC, THC+CBD, and placebo in 243 patients with cancer-related cachexia. It was stopped early for futility — no significant differences in appetite or quality of life between groups [4] Weak / limited. A smaller earlier trial of dronabinol in cancer patients suggested appetite improvement Weak / limited [8]. Newer trials of nabilone in non-small-cell lung cancer have shown modest improvements in caloric intake and quality of life Weak / limited [9].
Whole-plant cannabis for cachexia. Survey and observational data suggest patients using inhaled or oral whole-plant cannabis report appetite improvement Anecdote. There are essentially no high-quality RCTs of smoked or vaporized cannabis specifically for cachexia endpoints.
Cachexia in non-cancer, non-HIV conditions. Heart failure, COPD, end-stage renal disease cachexia — almost no controlled cannabinoid data exists No data.
What doesn't work (or where evidence is weak/negative)
Cannabinoids for lean body mass gain in cancer cachexia. This is the disappointing finding. Even when appetite improves, controlled trials have not shown that cannabinoids reverse the loss of skeletal muscle that defines cachexia [4][5] [evidence:weak-to-negative]. Cachexia is driven by inflammatory cytokines (TNF-α, IL-6) and proteolytic pathways that appetite stimulation alone doesn't fix.
Dronabinol vs. megestrol acetate. In a head-to-head 469-patient trial by Jatoi and colleagues at NCCTG, megestrol acetate produced significantly more appetite improvement (75% vs 49%) and more weight gain (11% vs 3% gained ≥10% baseline weight) than dronabinol. Combining them offered no benefit over megestrol alone [5] Strong evidence. For pure efficacy on weight, megestrol is the better-supported drug.
CBD alone for cachexia. No good evidence that CBD-only products meaningfully affect appetite or weight in cachectic patients No data. CBD does not activate CB1 the way THC does.
'Cannabis cures cancer cachexia' claims. Marketing folklore, not science.
What we don't know
- Optimal dose, ratio, and route. Most trials used oral dronabinol at 2.5–20 mg/day. Whether inhaled cannabis, different THC:CBD ratios, or specific terpene profiles change outcomes is unstudied No data.
- Whether cannabinoids combined with anti-inflammatory or anabolic agents (megestrol, ghrelin agonists like anamorelin, omega-3s) produce additive benefit. Anamorelin is approved in Japan for cancer cachexia; combination data with cannabinoids is sparse No data.
- Whether cannabinoids affect cachexia mortality endpoints. Trials have been too short and too small.
- Pediatric cachexia. Almost no data.
- Long-term effects of chronic THC use in already-frail patients (cognitive, falls, cardiovascular).
Comparison with standard treatments
Standard pharmacologic options for cachexia include:
- Megestrol acetate (progestin): the most consistently effective appetite stimulant and weight-gain agent in cancer and AIDS cachexia Strong evidence [5]. Caveat: weight gained is largely fat and water, not lean muscle, and it carries thromboembolic risk.
- Corticosteroids (dexamethasone, prednisolone): short-term appetite and well-being improvement, but benefits fade after 3–4 weeks and adverse effects accumulate Strong evidence.
- Anamorelin (ghrelin receptor agonist): approved in Japan; improves lean body mass in cancer cachexia but not handgrip strength [evidence:moderate].
- Olanzapine (low-dose): emerging evidence for appetite and weight in cancer cachexia [evidence:moderate] [10].
- Nutritional support and resistance exercise: foundational, evidence-supported, often underused Strong evidence.
Where cannabinoids fit: a reasonable second- or third-line option when appetite and food enjoyment are the primary problems, when nausea co-exists (THC has antiemetic effects), or when patients can't tolerate megestrol or steroids. Not a first-line anti-wasting drug.
Risks and practical considerations
Cannabinoid-specific risks in this population:
- Sedation, dizziness, falls. Particularly concerning in elderly or debilitated patients Strong evidence.
- Cognitive effects and confusion. Higher risk in patients already on opioids, benzodiazepines, or with brain metastases.
- Tachycardia and orthostatic hypotension. Relevant in patients with cardiac disease or volume depletion.
- Drug interactions. THC and CBD are metabolized by CYP3A4 and CYP2C9/2C19; CBD in particular can inhibit metabolism of co-administered drugs (tacrolimus, warfarin, some chemotherapeutics) Strong evidence [11]. This matters enormously in oncology and transplant patients.
- Dysphoria and anxiety. More common in cannabinoid-naïve older adults.
- Cost and access. Dronabinol is expensive; coverage varies. Medical cannabis access depends on jurisdiction.
Practical starting points clinicians use: dronabinol 2.5 mg once or twice daily, titrated cautiously. Lower in the elderly. Nabilone 0.5–1 mg at bedtime is an alternative.
Again: this article is informational. Do not start, stop, or change cachexia treatment based on it. Talk to your clinical team.
Sources
- Peer-reviewed Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management. 1995;10(2):89-97.
- Peer-reviewed Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. Journal of Pain and Symptom Management. 1997;14(1):7-14.
- Peer-reviewed Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep. JAIDS. 2007;45(5):545-554.
- Peer-reviewed Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology. 2006;24(21):3394-3400.
- Peer-reviewed Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology. 2002;20(2):567-573.
- Peer-reviewed Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behavioural Pharmacology. 2005;16(5-6):297-313.
- Peer-reviewed Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Annals of Oncology. 2011;22(9):2086-2093.
- Peer-reviewed Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. Journal of Palliative Care. 1994;10(1):14-18.
- Peer-reviewed Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Supportive Care in Cancer. 2018;26(9):3029-3038.
- Peer-reviewed Sandhya L, Devi Sreenivasan N, Goenka L, et al. Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. Journal of Clinical Oncology. 2023;41(14):2617-2627.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Government U.S. Food and Drug Administration. Marinol (dronabinol) prescribing information. Approved indications include anorexia associated with weight loss in patients with AIDS. ↗
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Nausea — What the evidence actually says about using cannabis and cannabinoids to treat nausea and...